In a clinical trial, published in Food and Nutrition Sciences, 41 participants with mild gastrointestinal discomfort received either PhenActiv® or a placebo over a 6 week period.

At the conclusion of the study, participants who had been taking PhenActiv reported significant improvements in Irritable bowel syndrome and constipation symptoms.

This is great news for the 1 in 7 (15 %) of New Zealanders who are diagnosed with Irritable Bowel Syndrome (IBS).

The published paper can be viewed HERE.

‍

Waitaki has been an early and committed adopter of carbon emission reduction programmes, with continuous participation in the Toitu (previously known as CEMARS) scheme for 17 years.

Managing our environmental footprint is critical to the success of our business and this independently audited local programme reviews business practices and issues certification every 3 years.

Food production is a major impactor on water and greenhouse gas emissions so we are continuously and actively working to reduce our footprint and identify opportunities for further improvement now and into the future.

‍